Peer-influenced content. Sources you trust. No registration required. This is HCN.
Eyewire+
The FDA approved Lytenava as the first ophthalmic bevacizumab formulation for wet AMD. The decision moves bevacizumab beyond repackaged intravenous use, with launch logistics still pending.
Ophthalmology August 4th 2026
Medical Professionals Reference (MPR)
A novel oral extended-release minoxidil formulation produced significantly greater non-vellus hair counts and patient-reported coverage improvement than placebo in men with androgenetic alopecia at six months.
Dermatology May 8th 2026
Parkinson’s News Today
Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.
Neurology April 30th 2026
Sdamlo’s FDA approval offers a new oral solution option for delivering amlodipine, addressing administration challenges in patients who cannot tolerate tablets.
Cardiology April 24th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS